Indication
Brinsupri is indicated for the treatment of non-cystic fibrosis bronchiectasis (NCFB) in patients 12 years of age and older with two or more exacerbations in the prior 12 months.
Loading your page…
Loading your page…
Bronchiectasis;Lung Diseases
Marketing Authorisation Holder: Insmed Netherlands B.V.
EMA Authorisation: 18/11/2025
INN: Brensocatib
AI Drug & Interaction Analysis
Free account required
Ask Osler about Brinsupri: drug interactions and guideline evidence, with every claim numbered to its source. For reference and learning, not treatment advice.
Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.